1.
Dubrot J, Du PP, Lane-Reticker SK, et al. In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer. Nat Immunol. 2022;23(10):1495-1506. doi:10.1038/s41590-022-01315-x.
1.
Frangieh CJ, Melms JC, Thakore PI, et al. Multimodal pooled Perturb-CITE-seq screens in patient models define mechanisms of cancer immune evasion. Nat Genet. 2021;53(3):332-341. doi:10.1038/s41588-021-00779-1.
1.
Mathys H, Adaikkan C, Gao F, et al. Temporal Tracking of Microglia Activation in Neurodegeneration at Single-Cell Resolution. Cell Rep. 2017;21(2):366-380. doi:10.1016/j.celrep.2017.09.039.
1.
Nirschl CJ, Suárez-Fariñas M, Izar B, et al. IFNγ-Dependent Tissue-Immune Homeostasis Is Co-opted in the Tumor Microenvironment. Cell. 2017;170(1):127-141.e15. doi:10.1016/j.cell.2017.06.016.
1.
Patel SJ, Sanjana NE, Kishton RJ, et al. Identification of essential genes for cancer immunotherapy. Nature. 2017;548(7669):537-542. doi:10.1038/nature23477.
1.
Goods BA, Hernandez AL, Lowther DE, et al. Functional differences between PD-1+ and PD-1- CD4+ effector T cells in healthy donors and patients with glioblastoma multiforme. PLoS One. 2017;12(9):e0181538. doi:10.1371/journal.pone.0181538.
1.
Radke JB, Carey KL, Shaw S, et al. High Throughput Screen Identifies Interferon γ-Dependent Inhibitors of Toxoplasma gondii Growth. ACS Infect Dis. 2018;4(10):1499-1507. doi:10.1021/acsinfecdis.8b00135.
1.
Hu D, Notarbartolo S, Croonenborghs T, et al. Transcriptional signature of human pro-inflammatory T17 cells identifies reduced IL10 gene expression in multiple sclerosis. Nat Commun. 2017;8(1):1600. doi:10.1038/s41467-017-01571-8.
1.
Sarkizova S, Hacohen N. How T cells spot tumour cells. Nature. 2017;551(7681):444-446. doi:10.1038/d41586-017-07267-9.
1.
Pan D, Kobayashi A, Jiang P, et al. A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing. Science. 2018;359(6377):770-775. doi:10.1126/science.aao1710.